‘Just heard about this petition at the 3rd European Bone
network Meeting. The power of people, patients and their advocates is the way
forward to change this law and get access to new drugs for children/TYA with
cancer... I hope I have set up a train of emails in my department for all my
colleagues to do the same’
Bernadette Brennan, Consultant Paediatric
Oncologist, UK
This
is one of the thousand plus positive responses to the online campaign we ran
during September, Childhood Cancer Awareness month. The idea was cooked up by
five of us over the dinner table at the Childhood Cancer International
conference in Sweden in May. Three months later, our website
went live calling for ‘basic changes to European Law to speed up
access to newer, kinder and potentially better drugs for more children and
teenagers with cancer.’
E-petitions are of course ten a penny but our intention has been to use support garnered over September to demonstrate that there is a real desire for change within the childhood cancer community and to take this as ‘ammo’ when we push for reform of the Paediatric Medicines Regulation in the months ahead.
My belief is that the quality rather than the quantity of the support posted on the website gives our campaign its credibility. Major international networks like SIOPE and ITCC have signed up and, of equal value, grassroots organisations have recognised the relevance of the campaign to the ordinary families they represent. The big names of paediatric oncology have been willing to give their celebrity endorsement but what for me is equally telling are the messages from the carers and survivors of the desperate need for change.
Ida Borhan, Manager, Malaysia: “My daughter Irdina lost a battle no child should endure, let alone lose.”
Where do we take these messages? Well, we’ll be meeting members of the paediatric committee of the European Medicines Agency in November but our first stop was the Cancer Drugs Development Forum (CDDF) in London in the first week of October. CDDF are the platform responsible for knocking the Paediatric Medicines Regulation into shape and the two working group meetings there, though productive, included some surprising revelations. Until the dust has settled and we’ve made sense of what was said, I’ll leave reporting on where the process of reforming the Regulation now stands.